¼¼°èÀÇ Ã³¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀå
Prescription Dermatology Therapeutics
»óǰÄÚµå : 1798216
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 280 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ã³¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀåÀº 2030³â±îÁö 808¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 504¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ Ã³¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 8.2%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 808¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¿©µå¸§¡¤ÁÖ»ç Ä¡·áÁ¦´Â CAGR 10.4%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 223¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °Ç¼± Ä¡·áÁ¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 137¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 13.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ã³¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀåÀº 2024³â¿¡ 137¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 177¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 13.1%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 4.0%¿Í 7.9%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ã³¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ó¹æÀü ±â¹Ý ÇǺΰú Ä¡·á·ÎÀÇ ÀüȯÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ó¹æ ÇǺΰú Ä¡·áÁ¦´Â ÀÇ·áÀû °³ÀÔÀÌ ÇÊ¿äÇÑ Áߵ¿¡¼­ ÁßÁõÀÇ ÇǺΠÁúȯÀ» Ä¡·áÇϱâ À§ÇØ °í¾ÈµÈ Ä¡·á Ä«Å×°í¸®·Î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ½ÃÁß¿¡¼­ ÆÇ¸ÅµÇ´Â ½ºÅ²Äɾî Á¦Ç°°ú´Â ´Þ¸® °Ç¼±, ¾ÆÅäÇÇ ÇǺο°, ÁÖ»ç, ¿©µå¸§, ¿©µå¸§, ³óÆ÷¼º ¶¡»ù¿°, ÇÇºÎ¾Ï µî ¸¸¼º, ¿°Áõ¼º, °¨¿°¼º, ÀÚ°¡¸é¿ª¼º ÇǺÎÁúȯÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÇǺΠ°Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, ÇǺΰú ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í, Áúº´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Áö³­ 10³â°£ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇß½À´Ï´Ù.

Áö¼Ó¼º ¶Ç´Â ³­Ä¡¼º Áúȯ ȯÀÚ¿¡°Ô´Â °í±Þ ¿Ü¿ëÁ¦, °æ±¸¿ë ·¹Æ¼³ëÀ̵å, »ý¹°Á¦Á¦, Àü½Å ¸é¿ªÁ¶ÀýÁ¦ µîÀÌ Ã³¹æµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¹Ì¿ëÇǺΰú¿Í Ä¡·áÇǺΰúÀÇ °æ°èµµ ¸ðÈ£ÇØÁö°í ÀÖÀ¸¸ç, »ö¼ÒÄ§ÂøÀå¾Ö, Å»¸ð, ±¤°ú¹ÎÁõ¿¡ ´ëÇÑ ÀÓ»óÀûÀ¸·Î È¿°úÀûÀÎ ÇØ°áÃ¥À» ã´Â ȯÀÚµéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. »çȸÀÇ Åµµ°¡ Àû±ØÀûÀÎ ÇǺΠ°ü¸®·Î ¹Ù²î¸é¼­ °ú°Å¿¡´Â '¹Ì¿ë»óÀÇ °ñÄ©°Å¸®'·Î ¿©°ÜÁ³´ø Áõ»óµµ ÀÇ·áÀÇ ¿µ¿ªÀ¸·Î ÀÓº£µðµåµÇ°í ÀÖ½À´Ï´Ù.

ÇǺΰú ÀÇ»ç, ÀÏ¹Ý ³»°ú ÀÇ»ç, ¾Ë·¹¸£±â Àü¹®ÀǸ¦ Æ÷ÇÔÇÑ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õµéµµ Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Áø´Ü ÅøÀÌ °³¼±µÊ¿¡ µû¶ó Àü¹® Á¦Ç°À» ó¹æÇÏ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. º¸Çè Àû¿ë È®´ë, ÇǺΰú ¹æ¹® ȯÀÚ Áõ°¡, µðÁöÅРó¹æ Ç÷§Æû µîÀÇ ¿äÀÎÀÌ Ã³¹æÀü À̵¿·üÀ» ³ôÀ̰í ó¹æ ÁؼöÀ²À» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù.

¾î¶² °úÇÐÀû Áøº¸¿Í ºÐÀÚ Çõ½ÅÀÌ Ä¡·á ¿É¼ÇÀ» À籸¼ºÇϰí Àִ°¡?

ó¹æ ÇǺΰú ½ÃÀå¿¡¼­´Â Ä¡·á È¿°ú¿Í ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» Çâ»ó½ÃŰ´Â »õ·Î¿î ¿ø·áÀǾàǰ(API), Ç¥Àû »ý¹°Á¦Á¦, Àü´Þ ½Ã½ºÅÛÀÌ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ·¹Æ¼³ëÀ̵å, Ç×»ýÁ¦¿Í °°Àº ±âÁ¸ ¾à¹°Àº ÇöÀç ´õ ³ªÀº Áúº´ Á¶Àý°ú ÀûÀº ºÎÀÛ¿ëÀ» Á¦°øÇÏ´Â »õ·Î¿î ¸é¿ª Á¶ÀýÁ¦, ¼±ÅÃÀû JAK ¾ïÁ¦Á¦, ÀÎÅÍ·ùŲ Ç¥Àû ´ÜŬ·Ð Ç×ü, ÀÎÅÍ·ùŲ Ç¥Àû Ç×ü µîÀ¸·Î º¸¿ÏµÇ°Å³ª ´ëüµÇ°í ÀÖ½À´Ï´Ù.

µàÇǷ縿(¾ÆÅäÇÇÇǺο° Ä¡·áÁ¦), ¼¼Äí´©¸¿(°Ç¼± Ä¡·áÁ¦), ¾Æ´Þ¸®¹«¸¿(³óÆ÷¼º ¶¡»ù¿° Ä¡·áÁ¦) µîÀÇ »ý¹°Á¦Á¦´Â ¿Ü¿ëÁ¦°¡ µèÁö ¾Ê´Â ÁßÁõ ȯÀÚµéÀÇ Ä¡·á ¼ºÀûÀ» ȹ±âÀûÀ¸·Î °³¼±Çß½À´Ï´Ù. PDE4 ¾ïÁ¦Á¦, TYK2 Â÷´ÜÁ¦ µî ÀúºÐÀÚ Ä¡·áÁ¦µµ ƯÈ÷ »ý¹°Á¦Á¦ ºÒ³»¼º ȯÀÚ³ª Áõ»óÀÌ °æ¹ÌÇÑ È¯ÀÚ¸¦ ´ë»óÀ¸·Î Æò°¡ ¹× »ó¿ëÈ­µÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µîÀåÀ¸·Î Ä¡·áºñ¿ëÀÌ Àý°¨µÇ°í, ´Ù¾çÇÑ Áö¿ª¿¡¼­ÀÇ Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.

Á¦Çü ±â¼úµµ ¹ßÀüÇÏ¿© ¸¶ÀÌÅ©·Î½ºÇǾî Àü´Þ, Æû ±â¹Ý ºñÈ÷Ŭ, ³ª³ë ij¸®¾î¸¦ °­È­ÇÑ ¿Ü¿ëÁ¦·Î ÇǺΠħÅõ¼º, ¾ÈÁ¤¼º, ȯÀÚ ¼øÀÀµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ±â¾÷Àº ƯÈ÷ Áö·ç¼º ÇǺο°À̳ª ¾à¹° ³»¼º ¿©µå¸§°ú °°Àº Ä¡·á ÀúÇ×¼º Áúȯ¿¡ ´ëÇØ ¾à¸®À¯Àüü ½ºÅ©¸®´×°ú AI¸¦ ÅëÇÑ Ä¡·á ¸ÅĪÀ» ÅëÇÑ °³ÀθÂÃãÇü ÇǺΰúÇп¡ ´ëÇÑ ÅõÀÚ¸¦ ÁøÇàÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐÀ» Çü¼ºÇϴ ȯÀÚ ºÎ¹®, º´ÅÂ, ä³ÎÀº ¹«¾ùÀΰ¡?

10´ë¿Í ÀþÀº ¼ºÀÎÀº ¿©µå¸§°ú ¿©µå¸§ °ü·Ã ÈäÅÍÀÇ È®»êÀ¸·Î ÀÎÇØ ó¹æÀü ÇǺΰú ½ÃÀåÀÇ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¼ºÀÎÃþ, ƯÈ÷ 30-55¼¼ ¿¬·ÉÃþÀº ÁÖ»ç, ±â¹Ì, °£¹Ý, ¸¸¼º µÎµå·¯±â µîÀÇ Ä¡·á ¿µ¿ªÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ´ç´¢, ¸é¿ª·Â ÀúÇÏ µîÀÇ ÇÕº´ÁõÀ» ¾Î°í ÀÖ´Â °í·ÉÃþÀº Ç×Áø±ÕÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, Ç׿°Áõ¾à µî ÇǺΰú Ä¡·áÁ¦ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

°¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â Ä¡·á ºÐ¾ß´Â ¾ÆÅäÇÇÇǺο°, °Ç¼±, ÇÇºÎ¾Ï µîÀÔ´Ï´Ù. ȯ°æÀû ½ºÆ®·¹½º ¿äÀÎ, ÀÚ°¡¸é¿ª À¯¹ß ¿äÀÎ, »ýȰ½À°üÀÇ º¯È­´Â Àü ¼¼°è¿¡¼­ ¸¸¼º ÇǺÎÁúȯÀ» ¾ÇÈ­½Ã۰í ÀÖ½À´Ï´Ù. µµ½ÃÈ­, °øÇØ, Àå½Ã°£ ½ºÅ©¸°¿¡ ³ëÃâµÇ´Â °Íµµ »êÈ­ ½ºÆ®·¹½º¿Í ±¤³ëÈ­ °ü·Ã ÇǺΠÁúȯÀÇ ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ó¹æÀü Á¶Á¦´Â Á¡Á¡ ´õ µðÁöÅÐ ¾à±¹ ¹× Àü¹® ¾à±¹ ä³Î·Î À̵¿Çϰí ÀÖ½À´Ï´Ù. ¿ø°Ý ÇǺΰú´Â ƯÈ÷ ¼­ºñ½º°¡ ºÎÁ·ÇÑ ¿ÀÁö ½ÃÀå¿¡¼­ Áø´Ü°ú Ä¡·á ½ÃÀÛ¿¡ ÀÖÀ¸¸ç, Áß½ÉÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Àü¹® ¾à±¹, ÇǺΰú Àü¹® üÀÎ, µðÁöÅÐ Ç÷§ÆûÀº ÀÚµ¿ ¸®ÇÊ, °¡»ó Áø·á, AI¸¦ Ȱ¿ëÇÑ Áõ»ó ÃßÀûÀ» ÅëÇØ ÄÄÇöóÀ̾𽺸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ó¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

¼¼°è ó¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº ¸¸¼º ÇǺÎÁúȯÀÇ À¯º´·ü Áõ°¡, ÇǺΰú Àü¹®ÀÇÀÇ Àúº¯ È®´ë, ¾à¹° ºÐÀÚ ¹× Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ °­·ÂÇÑ ±â¼ú Çõ½ÅÀÔ´Ï´Ù. ÇǺΠ°Ç°­ÀÌ Àü½Å °Ç°­ ¹× »îÀÇ ÁúÀÇ ÇÙ½ÉÀ¸·Î ¿©°ÜÁö¸é¼­ È¿°úÀûÀ̰í ÀÇÇÐÀûÀ¸·Î °ü¸®µÇ´Â Ä¡·á¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Â÷¼¼´ë »ý¹°Á¦Á¦ ¹× ¸é¿ªÄ¡·áÁ¦ÀÇ »ó¿ëÈ­·Î Ä¡·á ÇÁ·ÎÅäÄÝÀÌ À籸¼ºµÇ¾î º¸´Ù ½Å¼ÓÇÑ Áúº´ ÅëÁ¦, Àç¹ß·ü °¨¼Ò, ȯÀÚ °á°ú °³¼±ÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í »õ·Î¿î ¿Ü¿ëÁ¦¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº Àú·ÅÇÑ °¡°Ý°ú Áö¿ªÀû Á¢±Ù¼ºÀÇ È®´ë¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÓ»ó½ÃÇè ¹× ÇǺΰú ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀο¡ ´ëÇÑ ÅõÀÚ È®´ë·Î Ä¡·áÀÇ ´Ù¾ç¼ºÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼ÒºñÀÚ µðÁöÅÐÈ­¿Í ¿ø°ÝÀÇ·áÀÇ µµÀÔÀº ó¹æÀü ¿Âº¸µù, ¸®ÇÊ ¹°·ù, ¼øÀÀµµ ¸ð´ÏÅ͸µÀÇ ¼ºÀåÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç ¹× ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀåÀº ÇǺΰú ÀÎÇÁ¶óÀÇ ¼ºÀå, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ÇǺΰú ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ °­·ÂÇÑ ¸ð¸àÅÒÀ» º¸À̰í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å, µðÁöÅÐ Çコ, ȯÀÚ Á᫐ ¸ðµ¨ÀÌ À¶ÇյǸ鼭 ÇâÈÄ 10³â°£ ó¹æ ÇǺΰú Ä¡·áÁ¦ ½ÃÀåÀº Àü ¼¼°è¿¡¼­ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(¿©µå¸§¡¤ÁÖ»ç Ä¡·áÁ¦, °Ç¼± Ä¡·áÁ¦, ÇǺο°¡¤Áö¹æ°ú´ÙºÐºñ Ä¡·áÁ¦, Áø±Õ °¨¿°Áõ Ä¡·áÁ¦, ÇÇºÎ¾Ï Ä¡·áÁ¦, ±âŸ Á¦Ç° À¯Çü), À¯Åë ä³Î(º´¿ø ¾à±¹, ¼Ò¸Å ¾à±¹, ÅëÆÇ ¾à±¹)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

´ç»ç´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Äõ¸® ÇÏ´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Prescription Dermatology Therapeutics Market to Reach US$80.8 Billion by 2030

The global market for Prescription Dermatology Therapeutics estimated at US$50.4 Billion in the year 2024, is expected to reach US$80.8 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Acne & Rosacea Drugs, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$22.3 Billion by the end of the analysis period. Growth in the Psoriasis Drugs segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.7 Billion While China is Forecast to Grow at 13.1% CAGR

The Prescription Dermatology Therapeutics market in the U.S. is estimated at US$13.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.7 Billion by the year 2030 trailing a CAGR of 13.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Prescription Dermatology Therapeutics Market - Key Trends & Drivers Summarized

What Is Propelling the Shift Toward Prescription-Based Dermatology Therapies?

Prescription dermatology therapeutics represent a growing category of treatments designed to address moderate to severe skin conditions requiring medical intervention. Unlike over-the-counter skincare solutions, these therapies are used to treat chronic, inflammatory, infectious, and autoimmune dermatological conditions such as psoriasis, atopic dermatitis, rosacea, acne vulgaris, hidradenitis suppurativa, and skin cancers. With rising awareness of skin health, better access to dermatological care, and growing disease prevalence, the market has expanded significantly over the past decade.

Patients with persistent or recalcitrant conditions are increasingly being prescribed advanced topicals, oral retinoids, biologics, and systemic immunomodulators. The line between cosmetic and therapeutic dermatology is also blurring, with more patients seeking clinically validated solutions for pigmentation disorders, hair loss, and photodamage. As societal attitudes shift toward proactive skin management, even conditions once dismissed as “cosmetic nuisances” are being brought under the medical care umbrella.

Healthcare providers, including dermatologists, general physicians, and allergists, are also more inclined to prescribe specialty products amid greater disease awareness and improved diagnostic tools. Factors such as insurance coverage expansion, increased patient visits to dermatologists, and digital prescription platforms are amplifying prescription fill rates and enhancing adherence.

Which Scientific Advances and Molecule Innovations Are Reshaping Therapeutic Options?

The prescription dermatology market has seen a surge in new active pharmaceutical ingredients (APIs), targeted biologics, and delivery systems that have elevated the efficacy and safety profile of treatments. Traditional agents such as corticosteroids, retinoids, and antibiotics are now being complemented or replaced by novel immunomodulators, selective JAK inhibitors, and interleukin-targeting monoclonal antibodies that offer better disease control and fewer side effects.

Biologics such as dupilumab (for atopic dermatitis), secukinumab (for psoriasis), and adalimumab (for hidradenitis suppurativa) have dramatically improved outcomes in severe cases where topical agents fail. Small molecule therapies like PDE4 inhibitors and TYK2 blockers are also being evaluated and commercialized, especially for patients intolerant to biologics or with milder symptoms. The advent of biosimilars is reducing treatment costs and improving accessibility across different regions.

Formulation technologies have also advanced, with microsphere delivery, foam-based vehicles, and nanocarrier-enhanced topicals improving skin penetration, stability, and patient compliance. Companies are investing in personalized dermatology through pharmacogenomic screening and AI-guided therapeutic matching, especially for treatment-resistant conditions like seborrheic dermatitis or drug-resistant acne.

Which Patient Segments, Conditions, and Channels Are Shaping Market Dynamics?

Teenagers and young adults form a large proportion of the prescription dermatology market, particularly due to the widespread incidence of acne and acne-related scarring. Adult segments-especially those aged 30-55-are contributing to growth in therapeutic areas such as rosacea, melasma, and chronic urticaria. Geriatric patients, often managing comorbidities like diabetes or immune compromise, drive demand for antifungal, antiviral, and anti-inflammatory dermatological therapies.

The fastest-growing therapeutic segments include atopic dermatitis, psoriasis, and skin cancer. Environmental stressors, autoimmune triggers, and lifestyle changes are exacerbating chronic skin conditions globally. Urbanization, pollution, and prolonged screen exposure are also contributing to dermatological disorders related to oxidative stress and photoaging.

Prescription fulfillment is increasingly shifting toward digital and specialty pharmacy channels. Teledermatology is playing a central role in diagnosis and treatment initiation, particularly in underserved or remote markets. Specialty pharmacies, dermatology-focused chains, and digital platforms are improving compliance via automated refills, virtual consultations, and AI-enabled symptom tracking.

What Is Driving Growth in the Global Prescription Dermatology Therapeutics Market?

The growth in the global prescription dermatology therapeutics market is driven by the rising prevalence of chronic skin diseases, an expanding base of dermatology-trained physicians, and robust innovation in both drug molecules and delivery mechanisms. With skin health increasingly viewed as a core component of systemic health and quality of life, patient demand for effective, medically-supervised treatments is on the rise.

The commercialization of next-generation biologics and immunotherapies is reshaping treatment protocols, with faster disease control, reduced relapse rates, and improved patient outcomes. Regulatory approvals for biosimilars and novel topical formulations are enhancing affordability and expanding geographic access. In addition, growing investments in clinical trials and dermatology R&D pipelines are adding to therapeutic diversity.

Consumer digitalization and telemedicine adoption are supporting growth across prescription onboarding, refill logistics, and adherence monitoring. Markets in Asia-Pacific and Latin America are showing strong momentum due to growing dermatology infrastructure, rising disposable incomes, and awareness of dermatological health. As innovation, digital health, and patient-centric models converge, the prescription dermatology therapeutics market is positioned for strong global expansion over the next decade.

SCOPE OF STUDY:

The report analyzes the Prescription Dermatology Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Acne & Rosacea Drugs, Psoriasis Drugs, Dermatitis & Seborrhea Drugs, Fungal Infection Drugs, Skin Cancer Drugs, Other Product Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â